Lipid-peptide bioconjugation through pyridyl disulfide reaction chemistry and its application in cell targeting and drug delivery.
Animals
Cell Survival
/ drug effects
Cysteine
/ chemistry
Disulfides
/ chemistry
Drug Compounding
/ methods
Drug Delivery Systems
Endosomes
/ metabolism
Humans
Hydrogen-Ion Concentration
Lipids
/ chemistry
Liposomes
/ chemistry
Mice
Molecular Structure
Optical Imaging
/ methods
Peptides
/ chemistry
Proof of Concept Study
Pyridines
/ chemistry
Disulfide bonds
Endosomal escape
GALA
Smart liposomes
Targeting peptide
Journal
Journal of nanobiotechnology
ISSN: 1477-3155
Titre abrégé: J Nanobiotechnology
Pays: England
ID NLM: 101152208
Informations de publication
Date de publication:
21 Jun 2019
21 Jun 2019
Historique:
received:
09
04
2019
accepted:
10
06
2019
entrez:
23
6
2019
pubmed:
23
6
2019
medline:
7
9
2019
Statut:
epublish
Résumé
The design of efficient drug delivery vectors requires versatile formulations able to simultaneously direct a multitude of molecular targets and to bypass the endosomal recycling pathway of cells. Liposomal-based vectors need the decoration of the lipid surface with specific peptides to fulfill the functional requirements. The unspecific binding of peptides to the lipid surface is often accompanied with uncontrolled formulations and thus preventing the molecular mechanisms of a successful therapy. We present a simple synthesis pathway to anchor cysteine-terminal peptides to thiol-reactive lipids for adequate and quantitative liposomal formulations. As a proof of concept, we have synthesized two different lipopeptides based on (a) the truncated Fibroblast Growth Factor (tbFGF) for cell targeting and (b) the pH sensitive and fusogenic GALA peptide for endosomal scape. The incorporation of these two lipopeptides in the liposomal formulation improves the fibroblast cell targeting and promotes the direct delivery of cargo molecules to the cytoplasm of the cell.
Sections du résumé
BACKGROUND
BACKGROUND
The design of efficient drug delivery vectors requires versatile formulations able to simultaneously direct a multitude of molecular targets and to bypass the endosomal recycling pathway of cells. Liposomal-based vectors need the decoration of the lipid surface with specific peptides to fulfill the functional requirements. The unspecific binding of peptides to the lipid surface is often accompanied with uncontrolled formulations and thus preventing the molecular mechanisms of a successful therapy.
RESULTS
RESULTS
We present a simple synthesis pathway to anchor cysteine-terminal peptides to thiol-reactive lipids for adequate and quantitative liposomal formulations. As a proof of concept, we have synthesized two different lipopeptides based on (a) the truncated Fibroblast Growth Factor (tbFGF) for cell targeting and (b) the pH sensitive and fusogenic GALA peptide for endosomal scape.
CONCLUSIONS
CONCLUSIONS
The incorporation of these two lipopeptides in the liposomal formulation improves the fibroblast cell targeting and promotes the direct delivery of cargo molecules to the cytoplasm of the cell.
Identifiants
pubmed: 31226993
doi: 10.1186/s12951-019-0509-8
pii: 10.1186/s12951-019-0509-8
pmc: PMC6587267
doi:
Substances chimiques
Disulfides
0
Lipids
0
Liposomes
0
Peptides
0
Pyridines
0
GALA peptide
107658-43-5
Cysteine
K848JZ4886
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
77Subventions
Organisme : FP7 Ideas: European Research Council
ID : ERC-StG-338133
Références
Bioconjug Chem. 1999 Mar-Apr;10(2):186-91
pubmed: 10077466
J Leukoc Biol. 1999 Feb;65(2):270-9
pubmed: 10088611
Proc Natl Acad Sci U S A. 1975 Aug;72(8):3029-33
pubmed: 1059090
Gene Ther. 1999 Nov;6(11):1798-807
pubmed: 10602375
Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):745-50
pubmed: 10639150
Biochim Biophys Acta. 2000 Feb 15;1463(2):459-69
pubmed: 10675522
Bioconjug Chem. 2001 Jul-Aug;12(4):470-5
pubmed: 11459449
Bioconjug Chem. 2001 Sep-Oct;12(5):742-9
pubmed: 11562192
J Biol Chem. 2003 Jun 13;278(24):21831-6
pubmed: 12651849
Immunobiology. 1992 Aug;185(2-4):350-65
pubmed: 1452210
J Biol Chem. 1951 Nov;193(1):265-75
pubmed: 14907713
Adv Drug Deliv Rev. 2004 Apr 23;56(7):967-85
pubmed: 15066755
Biochim Biophys Acta. 2004 Jul 23;1658(1-2):80-8
pubmed: 15282178
Blood. 2004 Nov 15;104(10):3257-66
pubmed: 15284116
J Gene Med. 2005 Nov;7(11):1450-8
pubmed: 16025556
Annu Rev Pharmacol Toxicol. 2007;47:629-56
pubmed: 17014364
J Drug Target. 2006 Sep;14(8):536-45
pubmed: 17050120
Bioconjug Chem. 2007 Mar-Apr;18(2):590-6
pubmed: 17315942
Lipids. 1966 Jan;1(1):85-6
pubmed: 17805690
Bioconjug Chem. 2009 May 20;20(5):953-9
pubmed: 19388672
Nat Rev Immunol. 2009 Aug;9(8):581-93
pubmed: 19498381
Methods Mol Biol. 2010;605:377-91
pubmed: 20072895
Bioconjug Chem. 2010 Apr 21;21(4):653-62
pubmed: 20369815
J Cell Biochem. 2010 Oct 1;111(2):488-96
pubmed: 20533300
Curr Org Chem. 2010 Jan;14(2):138-147
pubmed: 20622973
J Cell Sci. 2011 Jan 1;124(Pt 1):5-8
pubmed: 21172818
Int J Pharm. 2011 Apr 15;408(1-2):173-82
pubmed: 21277964
Proc Natl Acad Sci U S A. 2011 Apr 12;108(15):6008-13
pubmed: 21444777
Nat Mater. 2011 May;10(5):389-97
pubmed: 21499315
Int J Oncol. 1993 Sep;3(3):473-6
pubmed: 21573387
J Control Release. 2011 Nov 7;155(3):442-8
pubmed: 21689699
Small. 2012 Jan 9;8(1):122-30
pubmed: 22102541
Eur J Lipid Sci Technol. 2011 Oct;113(10):1174-1187
pubmed: 22164124
J Microencapsul. 2012;29(3):262-76
pubmed: 22208705
Biophys J. 2011 Dec 7;101(11):2721-30
pubmed: 22261061
Biochemistry. 2012 Jun 12;51(23):4658-68
pubmed: 22591394
Cardiovasc Res. 2012 Aug 1;95(3):269-80
pubmed: 22678409
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Sensors (Basel). 2012;12(9):12347-60
pubmed: 23112716
Expert Opin Drug Deliv. 2013 May;10(5):593-609
pubmed: 23427944
J Biol Chem. 2013 Jun 14;288(24):17713-24
pubmed: 23653359
Sci Rep. 2013;3:2184
pubmed: 23851637
Eur Phys J E Soft Matter. 2013 Jul;36(7):75
pubmed: 23852577
Biomacromolecules. 2013 Aug 12;14(8):2822-9
pubmed: 23865598
Toxins (Basel). 2013 Oct 07;5(10):1698-722
pubmed: 24105401
Cell Death Dis. 2014 Mar 06;5:e1102
pubmed: 24603330
J Nanobiotechnology. 2014 Apr 01;12:11
pubmed: 24690265
Polym Chem. 2013 Apr 21;4(8):2464-2469
pubmed: 24761162
PLoS One. 2014 Sep 04;9(9):e106652
pubmed: 25187980
Chem Commun (Camb). 2015;51(2):273-275
pubmed: 25329926
J Chem Phys. 2014 Dec 14;141(22):22D517
pubmed: 25494788
Soft Matter. 2015 Apr 21;11(15):2993-3002
pubmed: 25731820
Biol Pharm Bull. 2015;38(2):270-6
pubmed: 25747986
Sci Rep. 2015 May 26;5:10112
pubmed: 26011176
Pharm Res. 2016 Mar;33(3):686-700
pubmed: 26572644
Front Pharmacol. 2015 Dec 01;6:286
pubmed: 26648870
J Control Release. 2016 May 10;229:130-139
pubmed: 26993425
ACS Omega. 2016 Sep 30;1(3):388-395
pubmed: 27713930
Nat Chem. 2017 Aug;9(8):751-761
pubmed: 28754944
J Pharm Sci. 2018 Jan;107(1):436-445
pubmed: 28826882
Biochem J. 1988 Nov 15;256(1):1-11
pubmed: 3066342
Methods Enzymol. 1987;149:111-9
pubmed: 3695954
Biochem Pharmacol. 1974 Sep 15;23(18):2495-531
pubmed: 4606365
Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10643-7
pubmed: 7504274
J Biol Chem. 1996 Dec 27;271(52):33647-53
pubmed: 8969234
Cancer Res. 1997 Apr 15;57(8):1447-51
pubmed: 9108444
Biochim Biophys Acta. 1997 Apr 26;1325(2):143-54
pubmed: 9168140
J Immunol Methods. 1997 May 26;204(2):205-8
pubmed: 9212838
J Immunol Methods. 1998 Apr 15;213(2):157-67
pubmed: 9692848
Clin Cancer Res. 1998 Oct;4(10):2455-61
pubmed: 9796978
Gene Ther. 1998 Jul;5(7):955-64
pubmed: 9813667